978 results about "Cervical carcinoma" patented technology

Vectors for DNA immunization against cervical cancer comprise a nucleic acid molecule encoding at least one non-toxic T-cell epitope of the E6 and / or E7 antigens of a strain of human papilloma virus (HPV) associated with cervical cancer, such as HPV-16, and a promoter operatively coupled to the nucleic acid molecule for expression of the nucleic acid molecule in a host to which the vector is administered.

The present invention provides multi-parameter analysis methods for determining the presence or absence of pre-cancerous or cancerous cells in a cervical sample and for screening cervical abnormality in a cervical sample. The invention also provides an apparatus and automated methods for screening cervical abnormality in a sample. The invention further provides a sampling device and a sample collection assembly for collecting cell samples, including cervical samples.

Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells derived from the umbilical cord blood retain high differentiation and proliferation abilities and exhibit very low graft-versus-host (GVH) reactions which are side effects caused by transplantation, and thus, can be transplanted to many patients.

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and / or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

Methods for treating, preventing, controlling the growth of and / or reducing the risk of developing cervical cancer, particularly in patients with cervical intraepithelial neoplasia are provided employing pharmaceutically acceptable preparations of DFMO. Methods for treating a patient having cervical intraepithelial neoplasia, which methods comprise administering DFMO alone or in combination with a cytotoxic or cytostatic agent, are also provided.

Embodiments of the invention provide methods, assays, and kits for detecting HPV infection, including infection by various HPV genotypes, early and / or late HPV-associated or HPV-specific proteins or antibodies. Detection of HPV DNAs, genomes, and / or oncoproteins by protein chips immunological assays can be used in early clinical screening for HPV infection and general diagnosis for cervical cancer and can be advantageous performed in a multiplexed test. Comparative detection of altered levels of HPV proteins and host proteins can performed in one or more assays. The polypeptides, recombinant proteins, antibodies, nucleic acids, and various detection methods thereof are particularly useful for diagnosing carcinomas of the uterine cervix and those at risk of developing cervical cancer.

Novel mercaptophenyl naphthyl methane compounds, their pharmaceutically acceptable salts and compositions comprised thereof are useful for the prevention or treatment of various medical indications associated with estrogen dependent diseases or syndromes related to osteoporosis, bone loss, bone formation, cardiovascular disorders, neurodegenerative disorders, menopausal disorders, physiological disorders, diabetes disorders, prostatic carcinoma, cancer of breast, cancer of uterus, cancer of the cervix and cancer of the colon, threatened or habitual abortion, obesity, ovarian development or function, post-partum lactation and depression.

Radical hysterectomy, i.e., a surgical method for treating cervical carcinoma, is put forward by Wertheim over 100 years before, becomes a classic of surgical treatment of cervical carcinoma, contributes to increasing the five-year survival rate of a patient suffering from cervical carcinoma by 80-90 percent, but has the defects of great damages, the occurrence rate of 70-85 percent of postoperative urinary bladder dysfunction, and influence on the postoperative life. Laparoscope cervical carcinoma radical-curing nerve-sparing surgery can be used for improving the urinary bladder function after a cervical carcinoma surgery and protecting hypogastric nerves, and is an important surgical link for protecting urinary bladder and rectum functions. Through simulation teaching, doctors are taught with a safe and effective method, students can contact ''patients'' by means of surgical skills before starting a surgery, and damages to nerves in the true surgery are avoided. In the simulation teaching, surgical instruments are needed, but above all model ''patients'' are needed. An anatomic plane and a repeatedly-operated simulation surgery model are taken as the teaching bases of surgeries, so that the students grasp anatomic positions and surgical separation skills. A surgical planar model disclosed by the invention promotes further development of surgery simulation teaching all over the world.

The present invention is an automated image analysis framework for cervical cancerous lesion detection. The present invention uses domain-specific diagnostic features in a probabilistic manner using conditional random fields. In addition, the present invention discloses a novel window-based performance assessment scheme for two-dimensional image analysis, which addresses the intrinsic problem of image misalignment. As a domain-specific anatomical feature, image regions corresponding to different tissue types are extracted from cervical images taken before and after the application of acetic acid during a clinical exam. The unique optical properties of each tissue type and the diagnostic relationships between neighboring regions are incorporated in the conditional random field model. The output provides information about both the tissue severity and the location of cancerous tissue in an image.

The invention provides an sgRNA combined with immunogene to inhibit high risk HPV expression, a gene knockout vector thereof, and an application of the sgRNA and the vector. The sgRNA sequences of a human papilloma virus 16 type gene suitable for CRISPR-Cas9 targeting editing and a human PD-1 gene are selected, and the plasmid vector of the sgRNA and a CRISPR-Cas9 nuclease gene expression vector are transferred to HPV16+ human cervical carcinoma cells and HPV16+ transplantation tumor-bearing mice, and can obviously inhibit HPV16 expression and inhibit tumor growth. The gene expression vector prepared in the invention has the advantages of simple method steps, good sgRNA targeting property, high CRISPR-Cas9 knockout efficiency, accurate targeting splicing of high risk HPV16 type and PD-1 genes, efficient reduction of the expression of the high risk HPV16 type gene, and obvious inhibition of the tumor growth through combined application.

PCT No. PCT / US97 / 11564 Sec. 371 Date Apr. 14, 1999 Sec. 102(e) Date Apr. 14, 1999 PCT Filed Jul. 8, 1997 PCT Pub. No. WO98 / 01132 PCT Pub. Date Jan. 15, 1998The present invention relates to specific adamantyl or adamantyl group derivative containing retinoid compounds induce apoptosis of cancer cells. These adamantyl retinoid derivatives are useful for the treatment of many cancers and solid tumors, especially androgen-independent prostate cancer, skin cancer, pancreatic carcinomas, colon cancer, melanoma, ovarian cancer, liver cancer, small cell lung carcinoma, non-small cell lung carcinoma, cervical carcinoma, brain cancer, bladder cancer, breast cancer, neuroblastoma / glioblastoma, and leukemia. Also, the invention relates to novel adamantyl or adamantyl group derivative compounds which are useful as active agents for the treatment or prevention of keratinization disorders and other dermatological conditions, and other diseases.

The invention searches the novel micromolecule inhibitor pyrazolo (1, 5-a) miazines compounds of cyclin-dependent kinase CDK9 (cyclin-dependent kinase) through the virtual screening of a computer, biometrically measures activity thereof, and validates interaction mechanism. The invention specifically comprises the following steps: the three-dimensional crystal conformation of the cyclin-dependent kinase family member CDK9 is obtained in a way of homology modeling; and micromolecule three-dimensional database is screened with DOCK (molecular docking). The invention uses a MTT tumor cell growth inhibition test to biometrically measures the activity of the selected compounds, researches the selected compounds pyrazolo (1, 5-a) miazines with high activety in a way of molecular mechanism, validates the inhibiting effect of the compounds to the activity of CDK9 kinase, and clarifies the interaction mechanism of the compounds for inhibiting the external activity and the molecule of various malignancies such as lung cancer, osteosarcoma, oophoroma, cervical carcinoma, breast cancer, etc.

A method of cancer treatment is provided that includes administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. An oral dose of water, in addition to normal water drinking, is administered to help alleviate feces hardening, a complication of ITE dosing. Subjects with cancers of skin, colon (or rectum), stomach, pancreas, kidney, bladder, soft tissue, and cervix, are preferably accepted for treatment or intervention.

The invention provides a DNA detection and analysis method based on Cas9 nuclease and application thereof. The method comprises the following three steps: (1) carrying out PCR amplification on targetDNAs; (2) treating a PCR amplification product by using a CAT method; and (3) carrying out PCR amplification with DNAs treated by using the CAT method as a template. The method can successfully detectL1 and E6 / E7 genes of HPV16 and HPV18 in human cervical carcinoma cells. According to the invention, the method successfully avoids current key bottleneck problems in nucleic acid hybridization, designing of specific PCR primers and the like in the fields of nucleic acid detection and typing.

The invention discloses application of dihydromyricetin in preparing a medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor. In particular, the application is to prepare medicines for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, preventing and treating arrest of bone marrow and baldness, resisting mutation, preventing and treating the generation of secondary tumors, preventing and treating tumor transfer, and preventing and treating breast cancer, cervical carcinoma, intestinal cancer and the like. The invention creatively finds that the dihydromyricetin has the effects of removing free radicals, inhibiting reaction chains of the free radicals, resisting the mutation, inhibiting the expression of the tumor gene, causing the death of tumor cells, preventing and treating the tumor generation, preventing and treating the secondary tumors and the transfer of the secondary tumors and preventing and treating infection. Therefore, as the medicine for preventing and treating untoward reactions in radiotherapy and chemotherapy of tumor, the dihydromyricetin can inhibit and alleviate chemical damage, prevent and treat damage of a mutagen and further prevent gene mutation or the secondary tumors; and by combination with the radiotherapy and chemotherapy, the effects of preventing untoward reactions in radiotherapy and chemotherapy of tumor and preventing generation of tumors are achieved.

The invention belongs to the technical field of biomedical engineering, and relates to an integration imaging system used for early stage cervical carcinoma detection and integrating fluorescent mesoscope imaging and optical coherence tomography (OCT). The integration imaging system comprises a fluorescent mesoscope imaging system and a spectrum OCT system. The fluorescent mesoscope imaging system comprises a laser light source, a polarizer, a polarized light spectroscope, a first dichroscope, a second dichroscope, an X-Y scanning galvanometer, an objective lens, a fluorescent detection part, a diffused light detection part and a computer, wherein the X-Y scanning galvanometer and the objective lens are shared by the spectrum OCT system. The spectrum OCT system comprises a low-coherent light source, a fiber polarization splitter, a focusing lens, the X-Y scanning galvanometer, the objective lens and a spectrograph. Ultraviolet light beams generated by the laser light source pass through the polarizer, the polarized light spectroscope and the first dichroscope and then are reflected through the second dichroscope, and samples generated by the low-coherent light source are collimated through the focusing lens and are combined with the ultraviolet light beams. The system improves diagnostic specificity through mutual evidence of organization function information and histomorphology information.

This invention relates to one polymer enzyme linkage reaction fluorescence test method to dialogue dangerous human body nipple shape virus and to isolate DNA sample HPV gene type to test one set of dangerous HPV infection from patient by the method, wherein, it belongs to life science and biological technique. This invention agent case comprises one fluorescence meter PCR technique as base of multi-layer polymer enzyme reaction composed of multiple HPV positive lead object, reaction lead object and fluorescence detector.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The invention belongs to the fields of gene engineering and oncology, and discloses a serum / plasma miRNA serum marker related to cervical carcinoma and precancerous lesions thereof and application thereof. The marker is single miR-21 or the combination of miR-21 and miR-29a. The marker and the primer thereof can be used for preparing diagnosis kits which are used for assistant early diagnosis of cervical carcinoma and precancerous lesions thereof.

Uterine cervical cancer Computer-Aided-Diagnosis (CAD) according to this invention consists of a core processing system that automatically analyses data acquired from the uterine cervix and provides tissue and patient diagnosis, as well as adequacy of the examination. The data can include, but is not limited to, color still images or video, reflectance and fluorescence multi-spectral or hyper-spectral imagery, coherent optical tomography imagery, and impedance measurements, taken with and without the use of contrast agents like 3-5% acetic acid, Lugol's iodine, or 5-aminolevulinic acid. The core processing system is based on an open, modular, and feature-based architecture, designed for multi-data, multi-sensor, and multi-feature fusion. The core processing system can be embedded in different CAD system realizations. For example: A CAD system for cervical cancer screening could in a very simple version consist of a hand-held device that only acquires one digital RGB image of the uterine cervix after application of 3-5% acetic acid and provides automatically a patient diagnosis. A CAD system used as a colposcopy adjunct could provide all functions that are related to colposcopy and that can be provided by a computer, from automation of the clinical workflow to automated patient diagnosis and treatment recommendation.

The invention specifically relates to a core-shell zinc oxide-silica nanoparticle, and a preparation method and application thereof, belonging to the technical field of nano-materials. The method comprises the following steps: subjecting lithium hydroxide and zinc methacrylate to hydrolysis at room temperature to produce luminous ZnO nanoparticles, adding siloxane monomers containing double bonds and azodiisobutyronitrile, carrying out heating to initiate polymerization so as to form a single organosilicon layer on the surface of the ZnO nanoparticles, then adding other siloxane and ammonia water, and carrying out hydrolysis at room temperature to form a silicon dioxide layer so as to prepare the core-shell zinc oxide-silica nanoparticles. The core of a core-shell zinc oxide-silica nanoparticle is a single zinc oxide luminous quantum dot and has a diameter of 2.7 to 4.6 nm; the shell of the nanoparticle is a thin silica layer; and the core-shell zinc oxide-silica nanoparticle is safe and nontoxic, has high quantum efficiency, stably emits light under continuous UV excitation in cells, can be used for preparing fluorescent labels for biological cells and is especially applicable to preparation of fluorescent labels for cervical carcinoma cells.

The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6 / E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6 / E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.

The invention discloses a colposcopy image-based cervical cancer detection method, device and terminal equipment and a computer readable storage medium. The method comprises the following steps of: ina bidirectional convolutional neural network-based cervical cancer detection model, positioning and extracting a cervical opening position of an obtained colposcopy image so as to generate an ROI image comprising a cervical cancer disease area; extracting a cutting edge of the ROI image through a bidirectional convolutional neural network so as to generate a cut image; and carrying out cancer grade classification on the cut image through a classification convolutional neural network so as to output a cervical cancer lesion grade and then rapidly and correctly obtain a cervical cancer detection result. According to the method, doctors that are lack of experiences can be helped to rapidly judge diseased regions, discover atypical diseased regions and judge the disease degrees and sampling regions, so that help and auxo-action are provided for discovering cervical cancer and precancerous lesions.

The invention relates to the pharmaceutical application of a medicament combination containing oil of zedoary turmeric. The medicament combination has new pharmaceutical application for preventing and treating various diseases, such as various HPV virus subtype infections, intraepithelial lesion(isl), papilloma and cervical carcinoma, and the like, in particular to high-risk HPV subtype infections. The medicament is prepared into various conventional formulations in the category of pharmaceutics, and the medicament combination can significantly prevent and treat multiple related diseases of HPV infection by clinical verification.

This invention relates to a suspension chip technology for the gene test to human papillomavirus used in testing and typing 26 kinds of papillomaviruses, in which, specific probes of which are crosslinked on 26 kinds of fluorescent microspheres to be reacted with the tested specimens then reacted with the report molecules labeled by the fluorescein to test the type specific nucleic acid of the virus by a fluorescent test device, which can test 26 kinds of ordinary HPV once and increases the test efficiency greatly and overcomes the shortcoming of missing testing the potential infections in the serology and immunity test method to realize early diagnosis to HPA diseases.

A tetrahydroindolone derivative and its use are disclosed. It can inhibit malignant tumor cell growth. It can be used for mammary gland cancer, lung cancer, uterus neck cancer, rectum cancer, liver cancer and blood cancer.

The invention discloses a targeted polypeptide capable of being specifically combined with tumors, particularly a targeted peptide capable of being specifically combined with liver cancer tissues and application thereof in diagnosis and treatment of liver cancer. The liver cancer targeted peptide is preferably HCC-47 of which the amino acid sequence is SQDIRTWNGTRS; and the liver cancer targeted peptide is specifically combined with the liver cancer tissues, and can not be specifically combined with cervical carcinoma cells Hela, mammary cancer cells MDA-MB231, kidney cancer cells CRL-1932 and lung cancer cells A549. The polypeptide is obtained by in-vitro biological elutriation by combining a bacteriophage display library and a living body cross sectioning technique. The polypeptide can be used in a molecular imaging preparation for early diagnosis of liver cancer. The polypeptide can also be used in targeted modification and preparation of drugs for treating liver cancer. The polypeptide can also be used for targeted modification on drug transport carriers, thereby providing a new way for diagnosing or treating patients with liver cancer.

The present invention relates to a method and kit for quantitative and qualitative determination of human papillomavirus, HPV, in a sample. More precisely, for quantitative and qualitative determination of oncogenic HPV to predict the risk of HPV infection resulting in cervical carcinoma. The method and kit enable simultaneous measurement of several oncogenic HPV types.